CYLD Antibody

中文名稱：

CYLD兔多克隆抗體
貨號：

CSB-PA865105LA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA865105LA01HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human pancreatic cancer using CSB-PA865105LA01HU at dilution of 1:100

Immunofluorescent analysis of Hela cells using CSB-PA865105LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) CYLD Polyclonal antibody
Uniprot No.：

Q9NQC7
基因名：

CYLD
別名：

BRSS antibody; CDMT antibody; Cyld antibody; CYLD gene antibody; CYLD_HUMAN antibody; CYLD1 antibody; CYLDI antibody; cylindromatosis (turban tumor syndrome) antibody; cylindromatosis 1 antibody; Deubiquitinating enzyme CYLD antibody; EAC antibody; HSPC057 antibody; KIAA0849 antibody; MFT antibody; MFT1 antibody; Probable ubiquitin carboxyl terminal hydrolase CYLD antibody; SBS antibody; TEM antibody; turban tumor syndrome antibody; Ubiquitin carboxyl-terminal hydrolase CYLD antibody; ubiquitin specific peptidase like 2 antibody; ubiquitin thioesterase CYLD antibody; Ubiquitin thiolesterase CYLD antibody; Ubiquitin-specific processing protease CYLD antibody; Ubiquitin-specific-processing protease CYLD antibody; USPL2 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Ubiquitin carboxyl-terminal hydrolase CYLD protein (269-435AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，CYLD Antibody (CSB-PA865105LA01HU)，的標記方式是Non-conjugated。對于CYLD Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA865105LB01HU	CYLD Antibody, HRP conjugated	ELISA
FITC	CSB-PA865105LC01HU	CYLD Antibody, FITC conjugated
Biotin	CSB-PA865105LD01HU	CYLD Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis. Negatively regulates NF-kappa-B activation by deubiquitinating upstream signaling factors. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis. Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation. Ability to remove linear ('Met-1'-linked) polyubiquitin chains regulates innate immunity and TNF-alpha-induced necroptosis: recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins. Regulates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation. Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regulating the kinase activity of RIPK1. Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades.
基因功能參考文獻：
1. A substantial number of CLL patient samples express sCYLD. PMID: 28566736
2. No genotype-phenotype correlation was found in tumor disorders of the skin appendages associated with mutations in the CYLD gene. PMID: 29974194
3. Catalytic domain mutation in CYLD gene is associated with osteosarcoma. PMID: 29807073
4. Studied the role of maternally expressed 3 (lncRNA-MEG3) as an antitumor lncRNA for malignant melanoma by regulating miR-499-5p/CYLD axis. PMID: 29808164
5. CYLD inhibits post-transcriptional regulation of RIG-I and MDA5 expression following TLR3 activation in MCs. CYLD may be involved in the pathogenesis of CKD PMID: 29166644
6. miR-197-3p-induced downregulation of CYLD promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines. PMID: 29286108
7. Knockdown of CYLD expression reversed the cell proliferation promotion by miR1288in in glioblastoma. PMID: 28901464
8. TNF phase III signalling displays ongoing TNFR1/NF-kappa B activation in monocytic cells. High- and low-sensitive genes are induced including differentially regulated A20. A20 strictly controls this signalling in an IKK- and partially RIP-dependent manner. The A20-mediated control mechanisms are supported by ABIN1 and CYLD. PMID: 28629782
9. Low expression of CYLD is associated with glioma. PMID: 28534976
10. theses data show that CYLD regulates the magnitude of ubiquitination of several major effectors of the EGFR pathway by assisting the recruitment of the ubiquitin ligase Cbl-b to the activated EGFR complex. PMID: 28572092
11. Through deceasing the expression of Cylindromatosis (CYLD), a K63-specific DUB and endogenous blocker of NF-kappaB signaling, miR-130b can in return sustain the persistent activation of NF-kappaB, which may promote the malignant progression of transitional cell carcinoma of bladder. PMID: 27391066
12. While previous reports have described CYLD as a regulator of DVL proteins; this data suggests the presence of a more complicated reciprocal regulatory mechanism in CML cell lines. PMID: 28840581
13. Thrombin-mediated MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. PMID: 27681433
14. MiR-767 acted as a role of tumor promoter by targeting CYLD in human melanoma. PMID: 29054757
15. SPATA2 has been described as a previously unrecognized factor in the linear ubiquitin chain assembly complex-dependent signaling pathways that serves as an adaptor between HOIP and CYLD, thereby enabling recruitment of CYLD to signaling complexes. PMID: 27545878
16. The data reveal SPATA2 as a high-affinity binding partner of CYLD and HOIP, and a regulatory component of linear ubiquitin chain assembly complex-mediated NF-kappaB signaling. PMID: 27591049
17. The current investigations identified a subset of HPV-positive HNSCCs with mutations in the genes TRAF3 (tumor necrosis factor receptor-associated factor 3) and CYLD (cylindromatosis lysine 63 deubiquitinase). Defects in TRAF3 and CYLD correlated with the activation of transcriptional factor nuclear factor kappaB, episomal HPV status of tumors, and improved patient survival. PMID: 28295222
18. The predicted PUB domain in the N-terminus of SPATA2 interacts with the USP domain of CYLD and SPATA2 is required for recruitment of CYLD to the TNF-alpha receptor-associated signaling complexes. PMID: 27307491
19. STAT3 and miR-181b control each other's expression in a positive feedback loop that regulates SFCs via CYLD pathway. PMID: 27189061
20. CYLD Promotes TNF-alpha-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells PMID: 27738385
21. Low CYLD expression is associated with hepatocellular carcinoma. PMID: 28184924
22. miR20a directly repressed the expression of CYLD, leading to activation of the NFkappaB pathway and the downstream targets, livin and survivin, which potentially induced GC chemoresistance. PMID: 27357419
23. Data show that cylindromatosis (CYLD) overexpression and livin knockdown might improve gemcitabine chemosensitivity by decreasing autophagy and increasing apoptosis in bladder cancer (BCa) cells. PMID: 27448305
24. aberrantly expressed miR-130b may regulate cell apoptosis and proliferation of human gastric cancer cells via CYLD, which appears to be a promising therapeutic target for gastric cancer PMID: 26711782
25. These results demonstrate the involvement of histone deacetylases in the down regulation of Cyld expression in hepatocellular carcinoma cells. PMID: 27570065
26. Novel CYLD germline mutations c.1821_1826+1delinsCT/L607Ffs*9, c.2666A>T/p.D889V and c.2712delT/p.905Kfs*8 were identified in unrelated Brooke-Spiegler Syndrome patients. PMID: 26329847
27. Study founds the levels of CYLD and SMAD7 significantly decreased in oral squamous cell carcinoma (OSSC) cells and proposes a model that CYLD suppresses OSCC metastases through SMAD7. Downregulation of CYLD appears to directly contribute to the distal metastases of primary OSCC and subsequently poor prognosis. PMID: 26982322
28. Haplotype analysis was performed for the patients with multiple familial trichoepithelioma type 1, patients with familial cylindromatosis and a patient with Brooke-Spiegler syndrome, all of whom carry the same heterozygous nonsense CYLD mutation. PMID: 26861065
29. Ultraviolet radiation induced CYLD translocation from the cytoplasm to microtubules, posttranslational modification and degradation in a proteasome-independent manner. PMID: 26717101
30. Deubiquitinase CYLD negatively regulates MyD88-mediated signaling by directly interacting with MyD88 and deubiquitinating nontypeable Haemophilus influenzae (NTHi)-induced K63-linked polyubiquitination of MyD88 at lysine 231. PMID: 26719415
31. CYLD interrupts the ERK- and p38-/AP-1 and c-Myc pathways to suppress Nrf2-operated antioxidative capacity, thereby enhancing oxidative stress in the heart. PMID: 25935309
32. Data suggest OPTN (optineurin) is involved in up-regulation of innate immunity in mitosis; mechanism involves phosphorylation/nuclear translocation of CYLD and phosphorylation/mitochondrial translocation of TBK1 (NF-kB-activating kinase). PMID: 25923723
33. CaMKII-mediated recruitment and upregulation of CYLD is expected to remove K63-linked polyubiquitins and facilitate proteasomal degradation at the postsynaptic density. PMID: 24614225
34. The deubiquitinating enzyme CYLD controls apical docking of basal bodies in ciliated epithelial cells. PMID: 25134987
35. Phenotype-genotype correlations for clinical variants caused by CYLD mutations. [Review] PMID: 25782638
36. we identified a novel mutation of the CYLD gene in a Chinese multiple familial trichoepithelioma family. PMID: 25117167
37. Low CYLD expression is associated with colorectal cancer. PMID: 25824771
38. Expression of nuclear CYLD is a novel prognostic factor for improved survival in patients with HCC undergoing liver resection or transplantation. PMID: 25329885
39. A recurrent R936X nonsense mutation of CYLD was identified in a large Chinese family with multiple familial trichoepithelioma. PMID: 25751345
40. Clinical management of patients with germline CYLD mutations is challenging and we discuss genetic counselling and surgical interventions PMID: 26370355
41. Data show that inhibiting the expression of cylindromatosis (CYLD) gene can suppress the proliferation and migration of umbilical vein endothelial cells (HUVECs). PMID: 26271973
42. TRAF-6 mediates S. p-induced PAI-1 expression, and CYLD inhibits PAI-1 expression probably through deubiquitinating TRAF-6 PMID: 26056944
43. DC-SIGN directs adaptive T helper cell type-2immunity to fucose-expressing pathogens via an IKKepsilon-CYLD-dependent signalling pathway leading to Bcl3 activation. PMID: 24867235
44. Here, we report a novel interaction between CYLD and MIB2 that supports the hypothesis that the CYLD/MIB2 interaction might play a pathogenic role in human cancer. PMID: 25565632
45. A heterozygous missense mutation (c.1112C>A) in the 9th exon of the CYLD gene was detected in some mother-daughter patients with multiple trichoepitheliomas. PMID: 25501176
46. CYLD displayed its ability to restrict the cells in G2 phase of cell cycle PMID: 25641919
47. the 35kDa CYLD cleaved factor generated by MALT-1 mediated proteolytic cleavage was conspicuously present in human T- ALL subjects of pediatric age group. PMID: 25130432
48. CYLD negatively regulates nontypeable Haemophilus influenzae-induced IL-8 expression via MKP-1-dependent inhibition of ERK. PMID: 25389768
49. Overexpression of non-SUMOylatable mutant CYLD in neuroblastoma cells reduced retinoic acid-induced NF-kappaB activation and differentiation of cells, but instead promoted cell death. PMID: 24909169
50. Report a novel heterozygous frameshift mutation c.1169_1170delCA (p.Thr390Argfs) of the CYLD gene in Chinese family with multiple familial trichoepithelioma. PMID: 25234269
顯示更多

收起更多
相關疾病：

Cylindromatosis, familial (FCYL); Multiple familial trichoepithelioma 1 (MFT1); Brooke-Spiegler syndrome (BRSS)
亞細胞定位：

Cytoplasm. Cytoplasm, perinuclear region. Cytoplasm, cytoskeleton. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle. Cytoplasm, cytoskeleton, cilium basal body.
蛋白家族：

Peptidase C19 family
組織特異性：

Detected in fetal brain, testis, and skeletal muscle, and at a lower level in adult brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney.
數據庫鏈接：

HGNC: 2584

OMIM: 132700

KEGG: hsa:1540

STRING: 9606.ENSP00000308928

UniGene: Hs.578973

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human